Acrobat
MS Word |
||
|
||
HIV Infection in Pregnancy
|
||
|
These plug-ins may be required for the content on this page:
IHS Plug-in Page Use site contact if unable to view a particular file |
Maternal Child
Perinatologist Corner - C.E.U/C.M.E. Modules
HIV Infection in Pregnancy
Sponsored by The Indian Health Service Clinical Support Center
4. Read the material on zidovudine
Prevention of vertical transmission of H.I.V. from mother to infant is the major goal of this protocol. In 1994 the 076 study clearly demonstrated that zidovudine (Z.D.V.) treatment of the mother during pregnancy and in labor, and treatment of the infant in the neonatal period, was able to reduce the transmission rate from 25% to 8%. This protocol should be made available to all known H.I.V.-infected patients, regardless of viral load, CD4+ counts, or other drug therapy:
Antepartum: Oral administration of 100 mg zidovudine 5 times daily, initiated at 14-34 weeks gestation and continued throughout the pregnancy.
Intrapartum: Intravenous administration of Z.D.V. in a 1-hour initial dose of 2 mg/kg, followed by a continuous infusion of 1 mg/kg/hr until delivery. (If planned cesarean, Z.D.V. should be begun 3 hours prior to surgery.)
Postpartum: Oral administration of ZDV syrup 2 mg/kg q6h to the newborn for the first 6 weeks of life beginning 8-12 h after birth. (If unable to take p.o., give Z.D.V. 1.5 mg/kg I.V. q6h.)
3. Background ‹ Previous | Next › 5. Other antiretrovirals
Content on this page may require:
Acrobat
MS Word
Accessibility · Disclaimer · Website
Privacy Policy · Freedom
of Information Act · Kid's Page · Contact 